Table 2.
Multivariate analysis of in vitro-derived predictors of response to therapy in a cohort of 88 normal karyotype AML patients.
| RFS (P-value) | RFS (P-value) | RD cycle1 | RD cycle1 | |
|---|---|---|---|---|
| ICE | 0.07 | 0.74 | ||
| V-ICE | 0.005 | 0.06 | ||
| A-ICE | 0.32 | 0.30 | ||
| AV-ICE | 0.72 | 0.47 | ||
| DA | 0.79 | 0.59 | ||
| Combined | 0.048 | 0.02 | ||
| BM Blasts | 0.55 | 0.72 | 0.29 | 0.13 |
| platelets | 0.06 | 0.07 | 0.21 | 0.22 |
| LDH | 0.09 | 0.09 | 0.24 | 0.32 |
| WBC | 0.15 | 0.047 | 0.12 | 0.16 |
| FLT3 ITD | 0.02 | 0.048 | 0.31 | 0.49 |
| FLT3 TKD | 0.22 | 0.20 | 0.55 | 0.62 |
| CEBPA | 0.85 | 0.85 | 0.08 | 0.15 |
| NPM1 | 0.72 | 0.91 | 0.0002 | 0.0002 |
| Total model | 0.002 | 0.002 | 0.045 | 0.018 |
Twenty-one patients had missing values for one or more of the clinical covariates or outcome measures used in the table. Patients were randomized to treatment with ICE, V-ICE, A-ICE or VA-ICE, and the predicted sensitivity to the treatment given was compared to clinical response after first treatment cycle, as well to relapse-free survival (RFS). P-values of association between predictors and outcome are shown. Combined uses a single score for each patient equal to the prediction score for the treatment given. Both V-ICE and the combined score are independent predictors of response, even when all other relevant factors are taken into account.